# Denis Lucquin

> Denis Lucquin is a Series A investor at Sofinnova Partners backing Biotechnology and Chemical. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners)
- Location: Paris, France
- Total investments: 11
- Last investment: Jul 2024
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/denis-lucquin/12/6a6/3b5

Denis Lucquin is a Managing Partner and Chairman of Sofinnova Partners. He is also a founder of Polytechnique Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 36% |
| Chemical | 3 | 27% |
| GreenTech | 1 | 9% |
| Agriculture | 1 | 9% |
| Health Care | 1 | 9% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 27% |
| Series B | 2 | 18% |
| Series C | 2 | 18% |
| Series G | 1 | 9% |
| Funding Round | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 18% |
| United States | 1 | 9% |
| The Netherlands | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Micropep Technologies | Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control. | $29.3M | Series B | Jul 25, 2024 |  |
| Micropep Technologies | Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control. | $9.3M | Series A | Jun 27, 2022 |  |
| Micropep Technologies | Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control. | $10.1M | Series A | Jul 08, 2021 |  |
| Micropep Technologies | Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control. | $4.4M | Series A | Mar 06, 2018 |  |
| Avantium | Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $42.1M | Series G | May 22, 2014 |  |
| BioAmber | BioAmber is a private US company registered in the state of Delaware. The company, formerly known as DNP Green Technology, changed its name to BioAmber following its acquisition of its joint venture with ARD. Following the transaction, they adopted the name BioAmber, which had been used to that point by the joint venture. | $30M | Series C | Feb 22, 2012 |  |
| Avantium | Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $48.2M |  | Jun 09, 2011 |  |
| Abionyx Pharma | ABIONYX Pharma is a biotech company discovering and developing innovative therapies for patients without existing or effective treatment. | $54.9M | Series C | Jul 25, 2010 |  |
| BioAmber | BioAmber is a private US company registered in the state of Delaware. The company, formerly known as DNP Green Technology, changed its name to BioAmber following its acquisition of its joint venture with ARD. Following the transaction, they adopted the name BioAmber, which had been used to that point by the joint venture. | $12M | Series A | Jan 17, 2010 |  |
| Abionyx Pharma | ABIONYX Pharma is a biotech company discovering and developing innovative therapies for patients without existing or effective treatment. | $53.5M | Series B | Nov 12, 2006 |  |

10 of 11 investments shown.

## Co-investors
- [IRDI](https://shizune.co/investors/profile/irdi-midi-pyrenees) — VC Fund, 4 deals together
- [EDF Ventures](https://shizune.co/investors/profile/edf-ventures) — VC Fund, 3 deals together
- [Fall Line Capital](https://shizune.co/investors/profile/fall-line-capital) — VC Fund, 3 deals together
- [FMC Ventures](https://shizune.co/investors/profile/fmc-ventures) — VC Fund, 3 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 3 deals together
- [Supernova Invest](https://shizune.co/investors/profile/supernova-invest) — VC Fund, 3 deals together

## About Sofinnova Partners

VC Fund · Paris, France

Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage.The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential topositively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs.It was headquartered in Paris, Ile-de-France in 1972.

5 contacts available at Sofinnova Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alain Tingaud | Venture Partner | https://shizune.co/investors/profile/alain-tingaud |
| Cedric Moreau | Partner | https://shizune.co/investors/profile/cedric-moreau |
| Dominique Verdier | Operations | https://shizune.co/investors/profile/dominique-verdier |
| Edward Kliphuis | Partner | https://shizune.co/investors/profile/edward-kliphuis |
| Jacques Theurillat | Partner, Crossover fund | https://shizune.co/investors/profile/jacques-theurillat-aad0 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Denis Lucquin invest in?

Denis Lucquin invests primarily in Biotechnology, Chemical and GreenTech startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Denis Lucquin last invest?

The most recent investment recorded for Denis Lucquin closed in Jul 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co